Search Results: test Market Analyses

Q3 Earnings Round-up

Below are some highlights from third quarter earnings reports recently released by biologics and biosimilar companies. Johnson & Johnson reported that Remicade (infliximab) sales declined more than 1% in the U.S. and more than 8% worldwide year-over-year.  During its earnings call, company executives explained that two-thirds of the decline in sales in Europe…

Read More

European Commission Report on Impact of Biosimilars Competition

The European Commission recently announced a report on the impact of biosimilar competition on price, volume and market share, based on full-year data from 2016. The report, prepared by QuintilesIMS, analyzed six established therapy areas with biosimilar competition—epoietin (EPO), G-CSF, hGH, anti-TNF, fertility/gonadotropin preparations, and recombinant human insulins—and identified four…

Read More

Brexit’s Impact on the Biosimilar Market

The United Kingdom’s referendum in favor of withdrawal from the European Union, colloquially known as “Brexit,” has already sent shockwaves through the business world, both within the UK, and abroad.  The impact of Brexit on the pharmaceutical industry has yet to be determined, but some fear that Brexit will cause…

Read More

EU Parliament Takes Steps to Increase Manufacture and Export of European Generics and Biosimilars During Protected Period

The Committee on Internal Market and Consumer Protection of the European Parliament has adopted its report on the “Single Market Strategy” – a strategy that aims to consolidate industries in European countries under one umbrella. Included in the report is a section on “consolidating Europe’s intellectual property framework.” The report…

Read More